Abstracts tagged "glucocorticoids"

Abstract Number: 1859 • ACR Convergence 2021
Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
Adam Geressu¹ and Marwan Bukhari², ¹Royal Lancaster Infirmary, Lancaster, United Kingdom, ²British Society for Rheumatology, London, United Kingdom
Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine…
Abstract Number: 0842 • ACR Convergence 2021
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
Lotte van Ouwerkerk¹, Isabell Nevins¹, Patrick Verschueren², Josef Smolen³, Robert Landewé⁴, Johannes Bijlsma⁵, Andreas Kerschbaumer³, Tom WJ Huizinga¹, Rene Westhovens⁶, Cornelia F. Allaart¹ and Sytske Anne Bergstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospitals Leuven - KULeuven, Leuven, Belgium, ³Medical University of Vienna, Vienna, Austria, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospitals KU Leuven, Maaseik, Belgium
Background/Purpose: Short-term glucocorticoid (GC) bridging therapy results in rapid suppression of disease activity during the initial treatment of rheumatoid arthritis (RA) patients with DMARDs. But…
Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Brian Coburn¹, Michael George¹, Joshua Baker¹, Jesse Hsu², Qufei Wu¹, Lang Chen³, Fenglong Xie³, Huifeng Yun⁴ and Jeffrey Curtis⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…
Abstract Number: 0856 • ACR Convergence 2021
Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
Alexander Hall¹, Michael Trevisonno¹, Elizabeth Murray¹, Omoakhe Tisor¹, Emily Stanford¹, Jacob Gaines¹, Noor Anvery¹ and Ellen Ginzler², ¹SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: The risk of COVID-19 infection among patients with Systemic Lupus Erythematosus (SLE) is poorly understood. Patients with SLE often take medications which modulate the…
Abstract Number: 1140 • ACR Convergence 2021
Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?
Alexandra Chop¹, Rajesh Kupuraju¹, Ruchi Patel¹, Kristen Salava¹, Madhuri Duggirala¹, Aparna Baburaj¹, Andrea Berger², Jason Brown¹ and David Bulbin³, ¹Geisinger Medical Center, Danville, PA, ²Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: Glucocorticoids are commonly prescribed for a multitude of indications, yet have many side effects, one of which is glucocorticoid induced osteoporosis (GIOP). The 2017…
Abstract Number: 1144 • ACR Convergence 2021
Underestimation of the Fracture Risk by the FRAX Formula in Chronic Glucocorticoid Users: A 10-year Longitudinal Validation Study
Chi Chiu Mok¹, Ling Yin Ho², Sau Mei TSE² and Kar Li Chan³, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Hong Kong
Background/Purpose: To compare the actual fracture incidence over 10 years in a longitudinal cohort of patients using glucocorticoids (GCs) with the risk prediction from FRAX…
Abstract Number: 1149 • ACR Convergence 2021
Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis
Saffa Iftikhar¹, Waleed Khokher², Ashu Acharya¹, Joan Gekonde³, Nithin Kesireddy², Rawish Fatima¹ and Nezam Altorok², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH, ³University of Toledo, Sylvania Township, OH
Background/Purpose: Glucocorticoids are commonly used in patients with rheumatologic conditions including but not limited to Rheumatoid Arthritis, Polymyalgia Rheumatica, Systemic Lupus Erythematous and so on.…
Abstract Number: 1264 • ACR Convergence 2021
Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study
James Sullivan¹ and Emily Littlejohn², ¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated…
Abstract Number: 1283 • ACR Convergence 2021
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
Karen Costenbader¹, Yoshiyuki Abe², Laurent Arnaud³, George Bertsias⁴, Norma Lynn Fox⁵, Mathew Gibb⁶, Anne Hammer⁵, Alexa Meara⁷, Holly Quasny⁸, David Roth⁵ and Tania Gonzalez-Rivera⁵, ¹Brigham and Women's Hospital, Belmont, MA, ²Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ⁴Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Greece, ⁵GlaxoSmithKline, Collegeville, PA, ⁶Veramed Ltd., Twickenham, United Kingdom, ⁷Ohio State University Wexner Medical Center, Columbus, OH, ⁸GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Glucocorticoids (GC) play an important role in rapid systemic lupus erythematosus (SLE) symptom relief. However, chronic GC use increases organ damage risk; and treatment…
Abstract Number: 0852 • ACR Convergence 2020
How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis
Konstantinos Tselios¹, Dafna Gladman², Haifa Al-Sheikh³, Jiandong Su⁴ and Murray Urowitz¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³King Faisal Specialist Hospital and Research Centre, Riyadh, Ar Riyad, Saudi Arabia, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
Background/Purpose: The existing guidelines for remission induction in lupus nephritis (LN) from both the ACR and the EULAR recommend initial prednisone doses of 0.5-1mg/kg/day. However,…
Abstract Number: 1940 • ACR Convergence 2020
In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached
Laura Felten¹, Nicolai Leuchten¹ and Martin Aringer², ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany
Background/Purpose: To investigate real life glucocorticoid (GC) dosing and relapse rates in patients with new onset giant cell arteritis (GCA) in a single center.Methods: Complete…
Abstract Number: 0853 • ACR Convergence 2020
Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) patients are usually treated with glucocorticoids even during periods of clinically quiescent disease. A recent study showed that abrupt glucocorticoid…
Abstract Number: 1958 • ACR Convergence 2020
Patterns and Impact of Long-term Glucocorticoid Use on RA Patients at Risk for Major Adverse Cardiac Events
Beth Wallace¹, Yuqing Gao², Punyasha Roul³, Bryant England³, Ted Mikuls³, Shirley Cohen-Mekelburg⁴, Daniel Clauw⁵, Rodney Hayward¹ and Akbar Waljee¹, ¹Michigan Medicine, VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, ²VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴Michigan Medicine/VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, ⁵Michigan Medicine, Ann Arbor, MI
Background/Purpose: One-quarter to one-third of RA patients use long-term glucocorticoids (GCs) despite their known, dose-dependent association with increased risk of major adverse cardiovascular (CV) events…
Abstract Number: 0005 • ACR Convergence 2020
Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists
Bella Mehta¹, Deanna Jannat-Khah², Carol Mancuso³, Anne Bass¹, Carine Moezinia⁴, Allan Gibofsky³, Susan Goodman⁵ and Said Ibrahim⁶, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York City, NY, ³Hospital for Special Surgery, New York City, ⁴Hospital for Special Surgery, New York, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁶Weill Cornell Medicine, Cleveland, OH
Background/Purpose: To investigate the perceptions and behaviors of rheumatologists in the United States (US) regarding the risk of COVID-19 for their autoimmune patients and the…
Abstract Number: 1083 • ACR Convergence 2020
Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment
Sabina Oreska¹, Hana Storkanova², Maja Spiritovic³, Barbora Hermankova⁴, Michal Vrablik⁵, Karel Pavelka⁶, Ladislav Šenolt⁶, Heřman Mann², Jiří Vencovský⁶ and Michal Tomcik⁷, ¹Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, ⁵3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by skeletal muscle and organ involvement and chronic course. Systemic inflammation, limited mobility, and glucocorticoid treatment can have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].